Key result
Optimal GDMT rises ~29 percentage points from screening to discharge in M-TEER patients.
Why the study?
Does the M-TEER clinical pathway from screening to discharge improve optimization of four-pillar heart failure guideline-directed medical therapy in patients with primary and secondary mitral regurgitation?
Observational (n=42)
No
Does the M-TEER clinical pathway from screening to discharge improve optimization of four-pillar heart failure guideline-directed medical therapy in patients with primary and secondary mitral regurgitation?
Heart failure medical therapy is frequently suboptimal at the time of M-TEER referral (only 45% on optimal GDMT at screening), though significant optimization can be achieved by the time of post-procedural discharge (74% optimal GDMT).
Answers are grounded in this paper and cite their sources.
GDMT optimization is feasible around M-TEER; hypothesis-generating for outcome impact in prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ćatić et al. (2026) conducted an observational in Primary or secondary mitral regurgitation undergoing mitral transcatheter edge-to-edge repair (M-TEER) (n=42). M-TEER pathway screening and post-procedural hospital care vs. Baseline status at initial M-TEER screening was evaluated on Optimal guideline-directed medical therapy (at least three drug classes at maximally tolerated doses with documented reasons for any limitation) (p=0.002). Optimal guideline-directed medical therapy in M-TEER patients increased from 45% at initial screening to 74% at hospital discharge, while four-pillar therapy rose from 33% to 57%.
Synapse has enriched 10 related papers. Consider them for comparative context: